TOP TEN perturbations for 1553141_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553141_at
Selected probe(set): 1553141_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553141_at (1553141_at) across 6672 perturbations tested by GENEVESTIGATOR:

doxorubicin study 3 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):4.6045666
Number of Samples:2 / 2
Experimental doxorubicin study 3
MCF7 cells treated with 2uM doxorubicin for 24 hours. ATC code:
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

LPS study 4 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):4.295536
Number of Samples:2 / 2
Experimental LPS study 4
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):4.1682453
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)

Relative Expression (log2-ratio):3.391694
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA cycT1)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control cycT1 depletion study 2 (shRNA)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.

HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)

Relative Expression (log2-ratio):-3.031252
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.
Control HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):3.0121517
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.8430672
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

pancreatic islet study 3 (re-differentiated; Whittier) / pancreatic islet study 3 (re-differentiated; PPRF; 2d)

Relative Expression (log2-ratio):2.6649265
Number of Samples:2 / 2
Experimental pancreatic islet study 3 (re-differentiated; Whittier)
Human pancreatic islets were from 2 male donors (46 and 54 years old, body mass index 21kg/m2 and 31.6kg/m2). Islets cells were expanded for 4 weeks and re-differentiated for 1 week according to Whittier protocol. Re-differentiation phase: After four passages (1 month expansion), cells were dispersed with Versene and cultured in serum-free CMRL-1066 medium supplemented with insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml). After 1 week of culture on HTB-9-coated plates, cells were harvested and forced to reaggregate overnight.
Control pancreatic islet study 3 (re-differentiated; PPRF; 2d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 2 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml.

IL-4; GM-CSF study 1 (early) / untreated monocyte sample

Relative Expression (log2-ratio):2.6589327
Number of Samples:6 / 12
Experimental IL-4; GM-CSF study 1 (early)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 6 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

TGF-ß study 8 (12h) / osteoarthritis study 6

Relative Expression (log2-ratio):2.406558
Number of Samples:3 / 6
Experimental TGF-ß study 8 (12h)
Synovial fibroblast samples isolated from affected knee of patients with osteoarthritis (OA) were stimulated by 10 ng/ml of TGF-ß in serum-free DMEM for 12 hours. Average duration of OA: 4.4 ± 0.6 years, all patients were rheumatoid factor negative. Patients were receiving non-steroidal antiinflammatory drugs. CRP: 13.2 ± 2.9 mg/l. Synovial fibroblasts were isolated from surgically obtained synovial membrane by trypsin/collagenase digestion, followed by negative purification using CD-14 Dynabeads® M-450. Before the TGF-ß stimulation, fibroblasts were cultured for four passages in DMEM medium supplemented with antibiotics and 10% FCS.
Control osteoarthritis study 6
Synovial fibroblast samples isolated from affected knee of patients with osteoarthritis (OA). Average duration of OA: 4.4 ± 0.6 years, all patients were rheumatoid factor negative. Patients were receiving non-steroidal antiinflammatory drugs. CRP: 13.2 ± 2.9 mg/l. Synovial fibroblasts were isolated from surgically obtained synovial membrane by trypsin/collagenase digestion, followed by negative purification using CD-14 Dynabeads® M-450. The fibroblasts were than cultured for four passages in DMEM medium supplemented with antibiotics and 10% FCS. Prior RNA isolation, the fibroblasts were washed in serum free DMEM.

Organism: Homo sapiens
Gene: 1553141_at
Selected probe(set): 228937_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553141_at (228937_at) across 6672 perturbations tested by GENEVESTIGATOR:

doxorubicin study 3 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):5.8644085
Number of Samples:2 / 2
Experimental doxorubicin study 3
MCF7 cells treated with 2uM doxorubicin for 24 hours. ATC code:
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

LPS study 4 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):5.83428
Number of Samples:2 / 2
Experimental LPS study 4
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)

Relative Expression (log2-ratio):4.6375713
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA cycT1)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control cycT1 depletion study 2 (shRNA)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.

LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):4.533991
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

PMA study 2 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):4.3887205
Number of Samples:3 / 2
Experimental PMA study 2
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

IL-4; GM-CSF study 1 (early) / untreated monocyte sample

Relative Expression (log2-ratio):4.2618027
Number of Samples:6 / 12
Experimental IL-4; GM-CSF study 1 (early)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 6 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

glioma study 16 (LN-18) / normal astrocyte sample

Relative Expression (log2-ratio):-4.0663905
Number of Samples:2 / 3
Experimental glioma study 16 (LN-18)
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-3.6983013
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinoma, NOS of the ovary (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

adefovir study 1 (50uM) / vehicle (DMSO) treated HepG2 sample

Relative Expression (log2-ratio):3.6869373
Number of Samples:3 / 21
Experimental adefovir study 1 (50uM)
HepG2 cells treated with compound: adefovir (50uM; CAS no.:106941-25-7) for 24 hours. Adefovir is non-hepatotoxic. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 sample
HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours.

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):3.5898771
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.